Harrow, Inc. (HROW)
NASDAQ: HROW · Real-Time Price · USD
26.66
+2.26 (9.26%)
At close: May 12, 2025, 4:00 PM
27.07
+0.41 (1.54%)
After-hours: May 12, 2025, 7:02 PM EDT
Harrow Revenue
Harrow had revenue of $47.83M in the quarter ending March 31, 2025, with 38.29% growth. This brings the company's revenue in the last twelve months to $212.86M, up 53.49% year-over-year. In the year 2024, Harrow had annual revenue of $199.61M with 53.32% growth.
Revenue (ttm)
$212.86M
Revenue Growth
+53.49%
P/S Ratio
4.48
Revenue / Employee
$557,220
Employees
382
Market Cap
978.41M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 199.61M | 69.42M | 53.32% |
Dec 31, 2023 | 130.19M | 41.60M | 46.95% |
Dec 31, 2022 | 88.60M | 16.12M | 22.24% |
Dec 31, 2021 | 72.48M | 23.61M | 48.30% |
Dec 31, 2020 | 48.87M | -2.29M | -4.48% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
HROW News
- 2 days ago - Harrow, Inc. (HROW) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 4 days ago - Harrow Announces First-Quarter 2025 Financial Results - Business Wire
- 7 days ago - Harrow to Report First Quarter 2025 Financial Results After Market Close on May 8, 2025 - Business Wire
- 18 days ago - NORDIC GROUP B.V. THROUGH ITS SUBSIDIARY NORDIC PHARMA, INC. - PRNewsWire
- 4 weeks ago - Harrow Expands VEVYE® Access for All Program to ImprimisRx's Klarity-C Patients - Business Wire
- 6 weeks ago - Harrow: When Cheaper Doesn't Mean Attractive (Rating Upgrade) - Seeking Alpha
- 6 weeks ago - Harrow, Inc. (HROW) Q4 2024 Earnings Conference Call - Seeking Alpha
- 6 weeks ago - Harrow Inc.: Roll The Dice For Strong Upside Prospects As Earnings Ramp - Seeking Alpha